Neuphoria Therapeutics Inc. (NEUP:NASDAQ) closed at $2.55 on November 13, 2026, down 1.16% on the day. The stock trades 53.9% below its 52-week high of $5.53 and 2.4% above its 52-week low of $2.49. Over the past year, it lost 45.7%. Neuphoria Therapeutics Inc. is part of the Health Care sector.
In 252 trading sessions since November 13, 2025, NEUP closed higher on 106 days (42%). Its best day was July 23, 2026 (+17.72%) and its worst was July 1, 2026 (-18.76%). The stock moved 10% or more in a single session 2 times. It opened at least 5% above the previous day's high 1 time.
Bionomics Nasdaq: BNOX ASX:BNO is a clinical-stage biopharmaceutical developing novel allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need. Bionomics is advancing its lead product candidate BNC210 an oral proprietary selective negative allosteric modulator of the 7 nicotinic acetylcholine receptor for the acute treatment of Social Anxiety Disorder and chronic treatment of Post-Traumatic Stress Disorder. Beyond BNC210 Bionomics has a strategic partnership with Merck & Co. Inc. known as MSD outside the United States and Canada with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimers disease and other central nervous system conditions.
Find more stocks like NEUP with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.